Has antihypoxic effect.
By directly affecting cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (enhancement of aerobic glycolysis and fat oxidation blockade).
Trimetazidine supports myocardial contractility, prevents the reduction of intracellular adenosine triphosphatase (ATP) and phosphocreatine. Under acidosis, it normalizes the functioning of ion channels of membranes, prevents the accumulation of potassium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemia zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase (CK) from cells and the severity of ischemic myocardial damage.
Trimetazidine reduces the frequency of angina attacks, reduces the need for nitrates, after 2 weeks of use increases exercise tolerance, and sharp fluctuations in blood pressure (BP) decrease. Reduces dizziness and tinnitus. In vascular pathology, the eye improves the functional activity of the retina.